Liquid pharmaceutical compositions comprising SGLT-2 inhibitors

1. A liquid pharmaceutical composition comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the polar organic solvents are selected from the group consisting of ethanol, propane-1,2-diol (propylene glycol), and propane-1,2,3-triol (glycerol), and the at least one SGLT-2 inhibitor comprises, 1-cyano-2-(4-cyclopropyl-benzyl)-4-(P-D-glucopyranos-1-yl)-benzene according to formula (I):

wherein the two or more polar organic solvents are provided in amounts such that the liquid pharmaceutical composition as a whole is characterized by a LogP-Parameter of less than zero and equal to or greater than −2.0.

2. The liquid pharmaceutical composition according to claim 1 , wherein 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene is the only SGLT-2 inhibitor contained in such liquid pharmaceutical composition.

3. The liquid pharmaceutical composition according to claim 1 , wherein said liquid pharmaceutical composition additionally comprises water or an aqueous buffer.

4. The liquid pharmaceutical composition according to claim 3 , wherein said liquid pharmaceutical composition has a measured pH value of from 3 to 9.

5. The liquid pharmaceutical composition according to claim 1 , wherein said liquid pharmaceutical composition additionally comprises one or more solubilizing agents, one or more viscosity-enhancing agents, or one or more flavors or sweeteners.

6. The liquid pharmaceutical composition according to claim 5 , wherein said one or more solubilizing agents are selected from the group consisting of: surfactants, anionic surfactants, non-ionic surfactants, hydrogenated castor oils, polyoxyethylene-polyoxypropylene block copolymers, polyethylene glycols, propylenglycol derivatives and mixtures thereof.

7. The liquid pharmaceutical composition according to claim 6 , wherein said one or more solubilizing agents are selected from the group consisting of: Sodium dodecyl sulphate (SDS), Cremophor RH 40 (PEG-40 Hydrogenated Castor Oil, Macrogol glycerol hydroxystearate 40), polysorbate 20, Lutrol F 68 (Poloxamer 188), PEG 300,propylenglycol monolaurate and mixtures thereof.

8. The liquid pharmaceutical composition according to claim 5 , wherein said one or more viscosity-enhancing agents are selected from the group consisting of: inorganic gel forming agents, organic gel forming agents, cellulose derivatives, and mixtures thereof.

9. The liquid pharmaceutical composition according to claim 8 , wherein said one or more viscosity-enhancing agents are selected from the group consisting of: hydroxyl ethyl cellulose, hydroxyl propyl methyl cellulose, silicon dioxide, and mixtures thereof.

10. The liquid pharmaceutical composition according to claim 5 , wherein said one or more flavors or sweeteners are selected from the group consisting of: honey flavor, lime/salvia flavor, jasmine flavor, lavender flavor, peppermint flavor, raspberry flavor, lemon flavor, herbs flavor, saccharine, aspartame, and mixtures thereof.

11. The liquid pharmaceutical composition according to claim 1 , wherein said liquid pharmaceutical composition does not comprise any apolar organic solvents, which are independently from each other characterized by a log 10 P value of equal to or higher than 0.

12. The liquid pharmaceutical composition according to claim 1 , wherein the polar organic solvents are independently of each other characterized by a negative decadic logarithmic partition coefficient (P) in an n-octanol/water system according to formula (II):

log 10 P n-octanol/water =concentration of unionized compound in n -octanol/concentration of unionized compound in water  (II).

13. The liquid pharmaceutical composition according to claim 1 , wherein said liquid pharmaceutical composition is suitable for direct administration to a mammal.

14. The liquid pharmaceutical composition according to claim 13 , wherein the mammal is a horse, cat or dog.

15. The liquid pharmaceutical composition according to claim 13 , wherein said liquid pharmaceutical composition is sterile.

16. The liquid pharmaceutical composition according to claim 1 , wherein said liquid pharmaceutical composition is a solution, an emulsion or a suspension.

17. The liquid pharmaceutical composition according to claim 16 , wherein said solution, an emulsion or a suspension has an NTU value of equal to or less than 10.0.

18. The liquid pharmaceutical composition according to claim 1 , wherein such liquid pharmaceutical composition is for oral or parenteral administration.

19. The liquid pharmaceutical composition according to claim 1 , wherein the composition further comprises:

(i) 0.5-5.0 g/100 mL (% w/w) 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene;

(ii) 10-60 g/100 mL (% w/w) propylene glycol;

(iii) 0-60 g/100 mL (% w/w) glycerol;

(iv) 0-20 g/100 mL (% w/w) ethanol;

(v) 0-1 g/100 mL (% w/w) flavor and/or sweetener;

(vi) 0-52 g/100 mL (% w/w) aqueous buffer;

(vii) 0-10 g/100 mL (% w/w) solubilizing agent; and

(viii) 0-5 g/100 mL (% w/w) viscosity-enhancing agent.

20. A liquid pharmaceutical composition selected from the group consisting of the following compositions 1 to 7:

Composition 1

Composition 2

Composition 3

Composition 4

Composition 5

Composition 6

Composition 7

Ingredient

[% (w/w)]

[% (w/w)]

[% (w/w)]

[% (w/w)]

[% (w/w)]

[% (w/w)]

[% (w/w)]

1-cyano-

1.5

1.5

1.5

1.5

1.5

1.5

1.0

2-(4-

cyclopropyl-

benzyl)-4-

(β-D-

glucopyranos-

1-yl)-

benzene

Propylene

60

60

60

60

60

60

52

glycol

Water

23.5

27.5

22.4

23.2

27.0

21.9

49.9

Glycerol

17.6

0.0

11.8

17.6

0.0

11.8

—

85%

Ethanol,

—

8

5

—

8

5

—

abs.

NaOH, 1N

4.71

5.51

4.49

4.63

5.41

4.39

—

Citric

0.36

0.42

0.34

0.35

0.41

0.33

—

acid,

monohydrate

Honey

—

—

—

0.15

0.15

0.15

—

flavor

Disodium

—

—

—

—

—

—

0.890

hydrogen

phosphate

dodecahydrate

Potassium

—

—

—

—

—

—

0.350

hydrogen

phosphate.

21. A kit-of-parts comprising:

(a) a liquid pharmaceutical composition according to claim 1 ; and

(b) a package leaflet including the information that the liquid pharmaceutical composition is to be used for the prevention or treatment of one or more medicinal indications in a subject in need of such prevention or treatment, which are selected from among the medicinal indications:

(i) a metabolic disorder of an equine animal, wherein the metabolic disorder is selected from the group consisting of: insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, regional adiposity, and mixtures thereof;

(ii) a metabolic disorder of an equine animal, wherein the metabolic disorder is selected from the group consisting of: laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction, Equine Metabolic Syndrome and mixtures thereof;

(iii) a metabolic disorder of a feline animal, wherein the metabolic disorder is selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function and mixtures thereof;

(iv) a metabolic disorder of a canine animal, wherein the metabolic disorder is selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction, musculoskeletal disorders, Syndrome X (metabolic syndrome), and mixtures thereof.

22. A process for producing the liquid pharmaceutical composition according to claim 1 , comprising the steps:

(i) mixing the polar organic solvents; and

(ii) dissolving 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene in the mixture resulting from step (i).

23. The process for producing the liquid pharmaceutical composition according to claim 22 , further comprising:

(iii) adding water to the mixture resulting from step (i).

24. The process for producing the liquid pharmaceutical composition according to claim 22 , further comprising:

(iii) dissolving further excipients in the mixture resulting from step (ii).

25. The process for producing the liquid pharmaceutical composition according to claim 24 , further comprising:

(iv) filtrating the mixture resulting from step (ii) or step (iii).

26. The process for producing the liquid pharmaceutical composition according to claim 25 , further comprising:

(v) performing an additional mixing step after one or more of steps (i), (ii), (iii) and (iv).

27. A method of treating a mammal in need of such treatment for a medical indication by administering to the mammal the liquid pharmaceutical composition of claim 1 , wherein the medical indication is selected from one or more of the following:

(i) a metabolic disorder of an equine animal, wherein the metabolic disorder is selected from the group consisting of: insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, regional adiposity, and mixtures thereof;

(ii)a metabolic disorder of an equine animal, wherein the metabolic disorder is selected from the group consisting of: laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction, Equine Metabolic Syndrome and mixtures thereof;

(iii) a metabolic disorder of a feline animal, wherein the metabolic disorder is selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function and mixtures thereof; and

(iv) a metabolic disorder of a canine animal, wherein the metabolic disorder is selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction, musculoskeletal disorders, Syndrome X (metabolic syndrome), and mixtures thereof.